Caroline C. Sigman

8.1k total citations · 1 hit paper
78 papers, 4.9k citations indexed

About

Caroline C. Sigman is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Caroline C. Sigman has authored 78 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 26 papers in Genetics and 23 papers in Cancer Research. Recurrent topics in Caroline C. Sigman's work include Estrogen and related hormone effects (18 papers), Inflammatory mediators and NSAID effects (12 papers) and Cancer Genomics and Diagnostics (9 papers). Caroline C. Sigman is often cited by papers focused on Estrogen and related hormone effects (18 papers), Inflammatory mediators and NSAID effects (12 papers) and Cancer Genomics and Diagnostics (9 papers). Caroline C. Sigman collaborates with scholars based in United States, Canada and United Kingdom. Caroline C. Sigman's co-authors include Gary J. Kelloff, Vernon E. Steele, James A. Crowell, Ronald A. Lubet, Charles W. Boone, Ernest T. Hawk, Judith R. Fay, Levy Kopelovich, Fausto Andreola and Luigi M. De Luca and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

Caroline C. Sigman

78 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

2005 499 citations Gary J. Kelloff, Howard I. Scher et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline C. Sigman United States	38	2.1k	1.1k	998	648	550	78	4.9k
Katsumi Imaida Japan	41	2.5k 1.2×	1.9k 1.8×	1.0k 1.0×	423 0.7×	832 1.5×	251	6.3k
Philippe Bougnoux France	46	2.5k 1.2×	2.0k 1.9×	1.7k 1.7×	308 0.5×	600 1.1×	182	6.7k
Franco O. Ranelletti Italy	44	2.4k 1.1×	925 0.9×	1.2k 1.2×	830 1.3×	338 0.6×	128	6.0k
Gerhard M. Kostner Austria	55	2.7k 1.3×	2.4k 2.2×	408 0.4×	562 0.9×	424 0.8×	260	10.5k
Junxuan Lü United States	52	3.5k 1.6×	1.2k 1.1×	735 0.7×	378 0.6×	491 0.9×	159	7.0k
Sharad S. Singhal United States	48	5.3k 2.5×	785 0.7×	1.8k 1.8×	449 0.7×	376 0.7×	197	7.6k
Yeong‐Shiau Pu Taiwan	42	2.5k 1.2×	840 0.8×	1.1k 1.1×	330 0.5×	1.5k 2.8×	312	7.0k
Gustav Schonfeld United States	61	3.1k 1.5×	2.3k 2.1×	417 0.4×	693 1.1×	258 0.5×	258	12.2k
Michihiro Mutoh Japan	33	2.2k 1.0×	954 0.9×	1.4k 1.4×	482 0.7×	362 0.7×	168	4.8k
Rachel Kerr United Kingdom	40	2.4k 1.1×	987 0.9×	3.3k 3.3×	466 0.7×	793 1.4×	153	6.5k

Countries citing papers authored by Caroline C. Sigman

Since Specialization

Citations

This map shows the geographic impact of Caroline C. Sigman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline C. Sigman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline C. Sigman more than expected).

Fields of papers citing papers by Caroline C. Sigman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline C. Sigman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline C. Sigman. The network helps show where Caroline C. Sigman may publish in the future.

Co-authorship network of co-authors of Caroline C. Sigman

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline C. Sigman. A scholar is included among the top collaborators of Caroline C. Sigman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline C. Sigman. Caroline C. Sigman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Keeney, Michael, Brent L. Wood, Benjamin D. Hedley, et al.. (2016). Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance. Blood. 128(22). 2907–2907. 1 indexed citations

Kelloff, Gary J., Caroline C. Sigman, & Howard I. Scher. (2015). Biomarker development in the context of urologic cancers. Urologic Oncology Seminars and Original Investigations. 33(6). 295–301. 14 indexed citations

Kelloff, Gary J. & Caroline C. Sigman. (2012). Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery. 11(3). 201–214. 185 indexed citations

Meyskens, Frank L., Gregory A. Curt, Dean E. Brenner, et al.. (2011). Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research. 4(3). 311–323. 36 indexed citations

Taube, Sheila E., Gary M. Clark, Janet Dancey, et al.. (2009). A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI Journal of the National Cancer Institute. 101(21). 1453–1463. 83 indexed citations

El‐Deiry, Wafik S., Caroline C. Sigman, & Gary J. Kelloff. (2006). Imaging and Oncologic Drug Development. Journal of Clinical Oncology. 24(20). 3261–3273. 59 indexed citations

Kelloff, Gary J., Ernest T. Hawk, & Caroline C. Sigman. (2004). Promising cancer chemopreventive agents. Humana Press eBooks. 9 indexed citations

Kelloff, Gary J., Ernest T. Hawk, & Caroline C. Sigman. (2004). Cancer Chemoprevention. Humana Press eBooks. 14 indexed citations

Kelloff, Gary J., Robert C. Bast, Donald S. Coffey, et al.. (2004). Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment. Clinical Cancer Research. 10(11). 3881–3884. 38 indexed citations

10.

Malone, Winfred F., Marjorie Perloff, James A. Crowell, Caroline C. Sigman, & Howard R. Higley. (2003). Fenretinide: a prototype cancer prevention drug. Expert Opinion on Investigational Drugs. 12(11). 1829–1842. 43 indexed citations

11.

Kelloff, Gary J., James A. Crowell, Vernon E. Steele, et al.. (2000). Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents. Journal of Nutrition. 130(2). 467S–471S. 382 indexed citations

12.

Hansen, Laura A., Caroline C. Sigman, Fausto Andreola, et al.. (2000). Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 21(7). 1271–1279. 212 indexed citations

13.

Kelloff, Gary J., Caroline C. Sigman, & Peter Greenwald. (1999). Cancer chemoprevention. European Journal of Cancer. 35(14). 2031–2038. 42 indexed citations

14.

Steele, Vernon E., Ernest T. Hawk, Levy Kopelovich, et al.. (1999). Lipoxygenase inhibitors as potential cancer chemopreventives.. PubMed. 8(5). 467–83. 204 indexed citations

15.

Kelloff, Gary J., Caroline C. Sigman, & Peter Greenwald. (1999). Cancer chemoprevention. European Journal of Cancer. 35(13). 1755–1762. 65 indexed citations

16.

Steele, Vernon E., Donya Bagheri, Douglas A. Balentine, et al.. (1999). Preclinical Efficacy Studies of Green and Black Tea Extracts. Proceedings of The Society for Experimental Biology and Medicine. 220(4). 210–212. 29 indexed citations

17.

Steele, Vernon E., Michael A. Pereira, Caroline C. Sigman, & Gary J. Kelloff. (1995). Cancer Chemoprevention Agent Development Strategies for Genistein. Journal of Nutrition. 125(3 Suppl). 713S–716S. 74 indexed citations

18.

Kelloff, Gary J., Charles W. Boone, James A. Crowell, et al.. (1995). Strategies for phase II cancer chemoprevention trials: Cervix, endometrium, and ovary. Journal of Cellular Biochemistry. 59(S23). 1–9. 24 indexed citations

19.

Kelloff, Gary J., James A. Crowell, Charles W. Boone, et al.. (1994). Strategy and planning for chemopreventive drug development: Clinical development plans. Journal of Cellular Biochemistry. 56(S20). 55–62. 37 indexed citations

20.

Kelloff, Gary J., Charles W. Boone, Vernon E. Steele, et al.. (1994). Mechanistic considerations in chemopreventive drug development. Journal of Cellular Biochemistry. 56(S20). 1–24. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact